Martina Greselin 1,2,3, Po-Jui Lu1,2,3, Alessandro Cagol1,2,3,4, Esther Ruberte1,2,3, Sabine Schädelin1,2,3,5, Lester Melie-Garcia1,2,3, Xinjie Chen1,2,3, Riccardo Galbusera1,2,3, Mario Ocampo-Pineda1,2,3, Matthias Weigel1,2,3,6, Jens Kuhle2,3, Ludwig Kappos2,3, Habib Ganjgahi7,8, Frederik Lange9, Thomas Nichols7,8, Dieter Häring10, Elizabeth Fisher10, Laura Gaetano10, Cristina Granziera1,2,3
1Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland
2Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland, Switzerland
3Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland., Switzerland
4Department of Health Sciences, University of Genova, Genova, Italy
5Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland., Switzerland
6University Hospital Basel, Basel, Switzerland
7Big Data Institute, Oxford, United Kingdom
8Statistics Department, University of Oxford, Oxford, United Kingdom
9Wellcome Centre for Integrative Neuroimaging, Oxford, United Kingdom
10Novartis Pharma AG, Basel, Switzerland
Presenting Author: Martina Greselin
Synopsis
Motivation:
Goals:
Approach:
Results:
Full abstract & presentation
The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.
Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.
To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.
1. H. Lassmann, J. Van Horssen, and D. Mahad, “Progressive multiple sclerosis: Pathology and pathogenesis,” 2012, Nature Publishing Group. doi: 10.1038/nrneurol.2012.168. [doi]
2. Disanto et al., “The Swiss Multiple Sclerosis Cohort-Study (SMSC): A prospective Swiss wide investigation of key phases in disease evolution and new treatment options,” PLoS One, vol. 11, no. 3, Mar. 2016, doi: 10.1371/journal.pone.0152347. [doi]
3. University Hospital, Basel, Switzerland, “Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis (INsIDER).” ClinicalTrials.gov ID: NCT05177523 Accessed: Oct. 29, 2025. [Online]. Available: https://www.clinicaltrials.gov/study/NCT05177523
4. S. Grahl et al., “Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis,” Mult Scler Relat Disord, vol. 29, pp. 124–129, Apr. 2019, doi: 10.1016/j.msard.2019.01.042. [doi]
5. F. La Rosa et al., “Multiple sclerosis cortical and WM lesion segmentation at 3T MRI: a deep learning method based on FLAIR and MP2RAGE,” Neuroimage Clin, vol. 27, Jan. 2020, doi: 10.1016/j.nicl.2020.102335. [doi]
6. J. Lange et al., “MMORF—FSL’s MultiMOdal Registration Framework,” Imaging Neuroscience, vol. 2, pp. 1–30, Mar. 2024, doi: 10.1162/imag_a_00100. [doi]